Summary
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
Stereotaxis Q2 Earnings Call Highlights
Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
Stereotaxis Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 46 | $85 | $63.71 | -$21.29 | -25.05% |
| GH George Henning PACIFIC GLOBAL INVESTMENT MANAGEMENT Co. | 18,900 | $37,880 | $26,176.5 | -$11,703.5 | -30.9% |
| BG Bart Gancher Intech Investment Management LLC | 19,239 | $35,436.4 | $27,319.38 | -$8,117.02 | -22.91% |
| OZI Omar Z. Idilby GMT CAPITAL Corp. | 126,581 | $232,909.04 | $174,681.78 | -$58,227.26 | -25% |
 Joseph Castro Nuveen LLC | 73,990 | $130,222 | $102,106.2 | -$28,115.8 | -21.59% |
Stereotaxis Inc. (STXS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stereotaxis Inc. ever had a stock split?
Stereotaxis Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | David L. Fischel CEO | AMEX Exchange | 85916J409 CUSIP |
| US Country | 131 Employees | - Last Dividend | 4 Nov 2013 Last Split | 12 Aug 2004 IPO Date |
Overview
Stereotaxis, Inc. is a pioneering company in the field of robotic systems, specializing in the design, manufacture, and marketing of advanced robotics, instruments, and information systems geared towards the interventional laboratory sector. Operating both in the United States and internationally, the company's cutting-edge technology primarily serves the purpose of enhancing the precision and safety of complex interventional procedures. Through its innovative solutions, Stereotaxis aims to facilitate physicians in navigating and manipulating devices within the human body with an unprecedented level of control and accuracy. Founded in 1990 and headquartered in Saint Louis, Missouri, Stereotaxis has established a strong reputation for its contribution to minimally invasive medical procedures, particularly in the realm of cardiology. The company’s commitment to innovation is also reflected in its strategic collaborations, such as with MAGiC catheter for cardiac ablation procedures, further emphasizing its role in advancing medical technology.
Products and Services
- Robotic Magnetic Navigation (RMN) Systems – Including the Genesis RMN and Niobe systems, these platforms represent the core of Stereotaxis' offerings. They facilitate the image-guided delivery of catheters and guidewires through blood vessels and heart chambers directly to the sites requiring treatment, enabling physicians to perform complex interventional procedures with enhanced precision and safety.
- Odyssey Information Solution – This comprehensive solution empowers hospitals and clinics to manage, control, record, and share interventional procedures in real-time across networks. The Odyssey platform is designed to streamline procedural workflows and enhance collaboration among medical professionals, irrespective of their physical location.
- Stereotaxis Imaging Model S X-Ray System – As part of its offering for a fully robotic interventional operating room, this single-plane, full-power x-ray system includes a c-arm, powered table, motorized boom, and monitors. It's optimized to work seamlessly with Stereotaxis’ robotic systems, providing clear and precise imaging during procedures.
- Disposables and Accessories – Among these, QuikCAS automated catheter advancement disposables stand out for their capability to advance electrophysiology catheters remotely, enhancing the efficiency and safety of cardiac interventions.
- Vdrive System – This system enhances the navigation and stability of diagnostic and therapeutic devices during interventional procedures. By improving the control over these devices, Vdrive contributes to the overall precision and success of interventions.
- V-Loop, V-Sono, and V-CAS Disposables – These components are designed to work with the Vdrive system, providing specific functionalities such as loop creation, ultrasound navigation, and catheter stability during interventional procedures. Each is developed to alleviate common challenges faced during complex medical interventions, thereby improving outcomes and patient safety.
